Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2013-09-17 Annual Report
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Financial Statements for the year ended 30 June 2011 25 pages 7.7MB
Annual Report Classification · 100% confidence The document is titled 'Financial Statements for the year ended 30 June 2011' and includes detailed financial statements such as the Directors' report, Auditor's Independence Declaration, consolidated statement of comprehensive income, statement of financial position, statement of changes in equity, statement of cash flows, and notes to the financial statements. It covers a full fiscal year and contains comprehensive financial data and analysis. The presence of an independent auditor's report and directors' declaration further confirms this is a full annual report. The document length is substantial (15,000 characters), indicating it is the full report rather than an announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2011
2013-09-17 English
Financial Statements for the year ended 30 June 2012 32 pages 4.8MB
Annual Report Classification · 100% confidence The document is titled 'Consolidated Financial Statements for the year ended 30 June 2012' and includes detailed financial statements such as the Directors' report, Auditor's Independence Declaration, consolidated statement of comprehensive income, statement of financial position, statement of changes in equity, cash flows, notes to the financial statements, directors' declaration, and independent auditor's report. The content covers a full fiscal year and provides comprehensive financial data and analysis. This matches the definition of an Annual Report (10-K) which is an official yearly report covering company activity and full financial performance. The document length is substantial (15,000 characters), indicating it is the full report rather than an announcement or summary. Therefore, the correct classification is 10-K with high confidence. FY 2012
2013-09-17 English
Financial Report for the half year ended 31 December 2012 17 pages 2.2MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim financial report for the half year ended 31 December 2012' and contains detailed financial statements including the Directors' report, consolidated statement of comprehensive income, financial position, changes in equity, and cash flows. It covers a six-month period, which is shorter than a full fiscal year, and includes substantive financial data and analysis. The presence of an auditor's independence declaration and detailed financial notes further supports that this is a comprehensive interim report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2013
2013-09-17 English
Updated Statement of Commitments 1 page 55.6KB
Regulatory Filings Classification · 90% confidence The document is very short (1158 characters) and contains a table titled 'Updated statement of commitments' with financial figures related to clinical development, trials, commercialization, capital expenditure, and working capital. There is no indication of a full financial report, regulatory certification, or detailed management discussion. The content appears to be an update or summary of financial commitments rather than a full report or announcement of voting results, management changes, or legal proceedings. Given the brevity and nature of the content, it does not fit the criteria for Annual Report, Interim Report, Earnings Release, or other detailed filings. It is more consistent with a Regulatory Filing (RNS) as a general update or miscellaneous financial information that does not fit other categories.
2013-09-17 English
Updated pro-forma balance sheet 3 pages 108.5KB
Capital/Financing Update Classification · 95% confidence The document contains detailed pro-forma financial statements including balance sheet, cash and cash equivalents, financial liabilities, and share capital notes. It discusses the impact of funds raised under a prospectus, convertible notes, share issues, and IPO-related transactions. The content is financial and accounting in nature, focusing on the company's financial position after capital raising events. The document length is 4278 characters, which is relatively short but contains substantive financial data and pro-forma adjustments, not just an announcement or a link to a report. It is not a simple announcement or certification but includes detailed financial figures and notes. The document is not a full annual report or interim report but rather a pro-forma financial statement update related to capital raising and IPO activities. This fits best under Capital/Financing Update (CAP) as it provides updated financial information reflecting capital raising and financing activities.
2013-09-17 English
Option Share Trust Plan 15 pages 125.4KB
Governance Information Classification · 95% confidence The document is titled 'Option Share Trust Plan Rules' for Regeneus Ltd and contains detailed terms and conditions related to an employee share option plan, including definitions, grant of options, vesting, exercise, lapse, forfeiture, allocation of shares, and restrictions on dealing with shares. It is a legal and governance document outlining the internal rules and procedures for the company's employee share option scheme. There is no financial data, earnings information, or regulatory filing announcements. The content fits the description of a governance document detailing internal rules and board-related policies rather than a financial report or announcement. Therefore, the appropriate classification is Governance Information (CGR).
2013-09-17 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.